Gujarat Attracts Global Healthcare Brands
Gujarat perhaps going to be the next hub of Indian healthcare enterprise. After Vicks and Colgate Palmolive, US-based Abbott Laboratories […]
Gujarat perhaps going to be the next hub of Indian healthcare enterprise. After Vicks and Colgate Palmolive, US-based Abbott Laboratories […]
According to Indian Pharmaceutical Alliance (IPA) the pharmaceutical industry has agreed in principle to enforce a code that will restrict […]
Prathap Reddys Apollo Group to invest `1,500 cr in Ahmedabad Apollo Hospitals Group will invest Rs 1,500 crore on increasing […]
Glenmark Pharmaceuticals has initiated voluntary recall of a skin ointment from the US after the drug exceeded the permissible impurity level.
Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.
[This article was published in the January 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
News
In an effort to control the quality of medicinal products, the government has brought out the Indian Pharmacopoeia, 2007, which lays down the standards for drugs produced or marketed in India.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.
The LORENZ Life Sciences Group announced recently that Orchid Chemicals & Pharmaceuticals, located in Chennai, India has chosen docuBridge as its eCTD Publishing and Management solution.